Zacks Research Has Negative Estimate for EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Zacks Research decreased their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a report issued on Thursday, January 30th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.57 per share for the quarter, down from their prior forecast of $0.58. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share.

Several other research firms also recently weighed in on EW. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a report on Thursday, January 16th. Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Trading Down 1.1 %

Shares of NYSE EW opened at $72.41 on Monday. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $42.71 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 3.65 and a beta of 1.11. The business’s 50 day moving average price is $72.49 and its 200-day moving average price is $69.85.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,000 shares of company stock worth $2,195,180. Insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC increased its stake in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.